SAILIFE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.5
| Stock Code | SAILIFE | Market Cap | 23,634 Cr. | Current Price | 1,114 ₹ | High / Low | 1,159 ₹ |
| Stock P/E | 68.0 | Book Value | 118 ₹ | Dividend Yield | 0.00 % | ROCE | 19.2 % |
| ROE | 14.9 % | Face Value | 1.00 ₹ | DMA 50 | 1,039 ₹ | DMA 200 | 931 ₹ |
| Chg in FII Hold | -0.24 % | Chg in DII Hold | 0.13 % | PAT Qtr | 102 Cr. | PAT Prev Qtr | 104 Cr. |
| RSI | 59.0 | MACD | 31.0 | Volume | 1,89,918 | Avg Vol 1Wk | 7,22,619 |
| Low price | 704 ₹ | High price | 1,159 ₹ | PEG Ratio | 0.48 | Debt to equity | 0.09 |
| 52w Index | 90.0 % | Qtr Profit Var | 13.8 % | EPS | 16.1 ₹ | Industry PE | 30.5 |
📊 Financials: SAILIFE has a market cap of ₹23,634 Cr. Quarterly PAT remained stable at ₹102 Cr. vs ₹104 Cr. (13.8% YoY growth). ROE at 14.9% and ROCE at 19.2% reflect strong efficiency and return metrics. Debt-to-equity ratio of 0.09 indicates very low leverage, supporting financial stability. EPS at ₹16.1 is modest relative to valuation multiples.
💹 Valuation: Current P/E of 68.0 is more than double the industry average of 30.5, suggesting significant overvaluation. P/B ratio (~9.4) is high compared to book value ₹118. PEG ratio at 0.48 indicates some growth support, but intrinsic value appears lower than CMP ₹1,114, limiting upside potential.
🏦 Business Model: SAILIFE operates in the pharmaceutical and life sciences sector, focusing on specialty formulations and research-driven products. Its competitive advantage lies in innovation, niche product portfolio, and strong execution. However, high valuations and dependence on regulatory approvals pose risks.
📉 Entry Zone: RSI at 59.0 suggests mildly overbought conditions, while MACD at 31.0 indicates bullish momentum. A potential entry zone could be around ₹1,000–₹1,050 for accumulation. Long-term investors may hold, given strong fundamentals, but valuation risks remain elevated.
Positive
- 📈 Strong ROCE (19.2%) and ROE (14.9%).
- 💰 Low debt-to-equity ratio (0.09).
- 🌐 Innovation-driven business model in life sciences.
Limitation
- ⚠️ High P/E (68.0) vs industry average (30.5).
- 📉 Elevated P/B ratio (~9.4).
- 🔄 Dependence on regulatory approvals and market cycles.
Company Negative News
- 📉 Decline in FII holding (-0.24%).
- ⚠️ Stock trading close to its 52-week high, limiting upside.
Company Positive News
- 📊 PAT growth YoY at 13.8%.
- 📈 Increase in DII holding (+0.13%).
Industry
- 💹 Industry PE at 30.5, much lower than SAILIFE’s 68.0.
- ⚡ Pharma and life sciences sector expanding globally.
- 🏦 Strong demand for specialty formulations and R&D-driven products.
Conclusion
⚖️ SAILIFE is a fundamentally strong, innovation-driven company with healthy returns and low leverage. However, valuations are stretched, limiting near-term upside. Long-term investors may accumulate near ₹1,000–₹1,050, but should remain cautious about high multiples and regulatory risks.
For a deeper perspective, you might explore SAILIFE peer comparison or a technical chart analysis to complement this fundamental view.